Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced a targeted realignment of its R&D portfolio to reinforce execution of its ...
Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on ...
Early-stage product development strategies to meet regulatory requirements across different markets Differences in ...
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
Understand the impact of IND delays on biotechnology companies and how they affect early-stage development and funding.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results